<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766049</url>
  </required_header>
  <id_info>
    <org_study_id>CAPPesq-0239/09</org_study_id>
    <nct_id>NCT02766049</nct_id>
  </id_info>
  <brief_title>Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus</brief_title>
  <official_title>Phase I/II Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <brief_summary>
    <textblock>
      The aim of this study was to assess tolerability and safety of three different formulations
      of an anti-HIV immunotherapy based on autologous dendritic cells (DCs) pulsed with HIV
      chemically inactivated with Aldrithiol™-2 (AT-2). Patients were chronically infected with
      HIV, naïve for antiretroviral drugs. A possible immunological and virological favorable
      impact was also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with ≥ grade 3 adverse events related to product</measure>
    <time_frame>51 weeks</time_frame>
    <description>AE graded by Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 1.0, December 2004</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in plasma viral load from baseline, over the observation period</measure>
    <time_frame>Baseline to 51 weeks</time_frame>
    <description>Log10 change in HIV RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with change in CD4+T cells from baseline, over the observation period</measure>
    <time_frame>Baseline to 51 weeks</time_frame>
    <description>Absolute number change of CD4+T cells</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>(a) DC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous dendritic cells (3x10e7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(b) DC 10e6+HIV-AT2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(c) DC 10e7+HIV-AT2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC</intervention_name>
    <description>Autologous dendritic cells (3x10e7)</description>
    <arm_group_label>(a) DC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC10e6+HIV-AT2</intervention_name>
    <description>Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV</description>
    <arm_group_label>(b) DC 10e6+HIV-AT2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC10e7+HIV-AT2</intervention_name>
    <description>Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV</description>
    <arm_group_label>(c) DC 10e7+HIV-AT2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with HIV infection;

          -  absence of antiretroviral therapy, antineoplastic therapy or the use of
             corticosteroids for at least six months prior to study entry;

          -  plasma viral load ≥ 1,000 copies / mL, stable (ie no variation &gt; 0.5 log) in the six
             months before the start of the study;

          -  blood CD4+ T cells ≥ 350 /mL, stable (ie no variation &gt; 25%) in the six months before
             the start of the study.

        Exclusion Criteria:

          -  individuals without proper venous access for blood and apheresis collection procedure.

          -  use of drugs, alcohol, psychiatric disorder or any condition that interferes with the
             ability of patients to follow the requirements of the study;

          -  history of diagnosis of HIV infection &lt;01 years;

          -  pregnancy or breast-feeding;

          -  use of antiviral therapy, in anticancer therapies or corticosteroids six months prior
             to study start;

          -  presence of chronic diseases, such as infection with hepatitis B (HBV) and C (HCV),
             human T-lymphotropic virus (HTLV) I / II or any condition that promotes immune system
             dysfunction, with the exception of HIV infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto JS Duarte, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <reference>
    <citation>Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004 Dec;10(12):1359-65. Epub 2004 Nov 28.</citation>
    <PMID>15568033</PMID>
  </reference>
  <reference>
    <citation>Oshiro TM, de Almeida A, da Silva Duarte AJ. Dendritic cell immunotherapy for HIV infection: from theory to reality. Immunotherapy. 2009 Nov;1(6):1039-51. doi: 10.2217/imt.09.68. Review.</citation>
    <PMID>20635918</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2016</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>clinical trial</keyword>
  <keyword>dendritic cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

